Omeros sells portion of OMIDRIA royalties for $125M; total capped payments of $188.4M through 2030

OMEROS CORP

Received $125M upfront from DRI Healthcare for partial sale of OMIDRIA royalties.
DRI gets capped payments: $1.67M in 2022, $13M in 2023, $20M in 2024, $25M/yr 2025-28, $26.25M 2029, $27.5M 2030.
Total payments to DRI capped at $188.4M; Omeros retains royalties above annual caps.
No recourse to Omeros assets beyond purchased receivables; no financial covenants.
Agreement terminates Dec 31, 2030 or when DRI receives all payments due.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.